Table of Content

Executive Summary
Scope and Definition
Market/Product Definition
Key Questions Answered
Analysis and Forecast Note

1. Global Aneurysmal Subarachnoid Hemorrhage Market: Industry Outlook
1.1 Market Overview
1.2 Epidemiological Analysis of Aneurysmal Subarachnoid Hemorrhage, By Region
1.3 Regulatory Landscape of Aneurysmal Subarachnoid Hemorrhage Market
1.3.1 Legal Requirement and Framework in the U.S.
1.3.2 Legal Requirement and Framework in the E.U.
1.3.3 Legal Requirement and Framework in Japan
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraint
1.6.4 Market Opportunities

2. Global Aneurysmal Subarachnoid Hemorrhage Market, by Drug Class, $Million, 2023-2035
2.1 Opioid Analgesic
2.2 Calcium Channel Blocker
2.3 Anticonvulsant
2.4 Other Drugs

3. Global Aneurysmal Subarachnoid Hemorrhage Market, by Region, $Million, 2023-2035
3.1 North America
3.1.1 Key Market Participants in North America
3.1.2 Business Drivers
3.1.3 Business Challenges
3.1.4 Market Sizing and Forecast
3.1.4.1 North America Aneurysmal Subarachnoid Hemorrhage Market, by Country
3.1.4.1.1 U.S.
3.2 Europe
3.2.1 Key Market Participants in Europe
3.2.2 Business Drivers
3.2.3 Business Challenges
3.2.4 Market Sizing and Forecast
3.2.4.1 Europe Aneurysmal Subarachnoid Hemorrhage Market, by Country
3.2.4.1.1 Germany
3.2.4.1.2 U.K.
3.2.4.1.3 France
3.2.4.1.4 Italy
3.2.4.1.5 Spain
3.3 Asia-Pacific
3.3.1 Key Market Participants in Asia-Pacific
3.3.2 Business Drivers
3.3.3 Business Challenges
3.3.4 Market Sizing and Forecast
3.3.4.1 Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Market, by Country
3.3.4.1.1 Japan
3.4 Rest-of-the-world
3.4.1 Key Market Participants in Rest-of-the-world
3.4.2 Business Drivers
3.4.3 Business Challenges
3.4.4 Market Sizing and Forecast

4. Aneurysmal Subarachnoid Hemorrhage Market: Competitive Landscape and Company Profiles
4.1 Competitive Landscape
4.1.1 Key Developments and Strategies
4.1.1.1 Funding Activities
4.1.1.2 Mergers and Acquisitions
4.1.1.3 Regulatory Approvals
4.1.1.4 Partnerships, Collaborations and Business Expansions
4.2 Company Profiles
4.2.1 Azurity Pharmaceuticals, Inc (Arbor Pharmaceuticals)
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Target Customers
4.2.1.4 Key Personnel
4.2.1.5 Analyst View
4.2.2 Grace Therapeutics, Inc.
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Target Customers
4.2.2.4 Key Personnel
4.2.2.5 Analyst View
4.2.3 BIT Pharma
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Target Customers
4.2.3.4 Key Personnel
4.2.3.5 Analyst View
4.2.4 Edge Therapeutics (PDS Biotechnology)
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Target Customers
4.2.4.4 Key Personnel
4.2.4.5 Analyst View
4.2.5 Idorsia Pharmaceuticals Ltd
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Target Customers
4.2.5.4 Key Personnel
4.2.5.5 Analyst View
4.2.6 TheraCryf (Evgen Pharma plc)
4.2.6.1 Overview
4.2.6.2 Product Portfolio
4.2.6.3 Target Customers
4.2.6.4 Key Personnel
4.2.6.5 Analyst View

5. Research Methodology

List of Figures
Figure: Global Aneurysmal Subarachnoid Hemorrhage Market, Market Overview
Figure: Global Aneurysmal Subarachnoid Hemorrhage Market, Epidemiological Analysis
Figure: Global Aneurysmal Subarachnoid Hemorrhage Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Aneurysmal Subarachnoid Hemorrhage Market, Competitive Landscape, January 2022-May 2025

List of Tables
Table: Global Aneurysmal Subarachnoid Hemorrhage Market, Regulatory Scenario
Table: Global Aneurysmal Subarachnoid Hemorrhage Market Dynamics, Impact Analysis